جستجوی استاد راهنمای دانشگاهی

Ram Samudralaمشاهده پروفایل

استاد

• Bioinformatics
• Computational Biology
• Drug Discovery
• +۱۰ مورد دیگر

Ram Samudrala is a Professor and Chief of the Division of Bioinformatics at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences . His research focuses on multiscale computational biology , integrating protein structure prediction , drug discovery , and translational science to address medical challenges. He leads the development of the CANDO platform for therapeutic drug discovery and co-directs the Informatics Core at the Clinical and Translational Sciences Institute. PhD in Computational Biology (University of Maryland, 1997) BA in Computing Science and Genetics (Ohio Wesleyan University, 1993) Postdoctoral Fellowship in Protein Folding (Stanford University, 1997-2001) His work spans structural biology , genomics , and computational drug design , with applications in dentistry , infectious diseases , and cancer . He has received prestigious awards including the NIH Director's Pioneer Award (2010) and multiple Wiki Science Prizes . Samudrala's group collaborates globally, emphasizing in silico methods followed by in vitro and in vivo validation. Key grants include $1.22M NIH NCATS ASPIRE Reduction-to-Practice Award and $4.5M NIH/NLM BRIGHT Training Grant . 2023 Finalist, Clinical and Translational Sciences Institute Clinical Research Achievement Awards 2016 MacArthur Foundation 100&Change Top 50 2008 Alberta Heritage Foundation Visiting Scientist Award 2005 NSF CAREER Award He directs the BRIGHT Short-Term Training Program and serves on multiple editorial boards and review panels. Samudrala's group maintains a Protinfo web server for structural predictions and the Bioverse framework for systems-level analyses.

Bradley E. Aouizeratمشاهده پروفایل

استاد

• Oral-Systemic Health
• Genomics
• Epigenetics
• +۱۲ مورد دیگر

Bradley E. Aouizerat is a Professor at the College of Dentistry, New York University (NYU) , with a strong focus on oral-systemic health, genomics, and translational research. His work bridges dentistry, immunology, and chronic disease, particularly in populations affected by HIV, cancer, and health disparities. Education: BS in Microbiology/Molecular Genetics – University of California at Los Angeles PhD in Microbiology/Molecular Genetics/Immunology – University of California at Los Angeles MAS in Master of Advanced Science Research in Clinical – University of California at San Francisco His research interests span epigenetics, gene expression, pain mechanisms, microbiome, sleep, and inflammation , with a strong emphasis on biomarker discovery and minority health. He has led studies on DNA methylation in oral cancer, cytokine profiles in HIV, and the role of mitochondrial genetics in diabetes. His work often integrates machine learning and longitudinal cohort data from major studies like the Women’s Interagency HIV Study (WIHS) and Multicenter AIDS Cohort Study (MACS). His recent publications (2021–2025) reflect a broad and impactful research program, with studies in oral cancer, HIV persistence, depression in chronic disease, lymphedema, sleep disruption, and gut microbiota . These works highlight his interdisciplinary approach, combining molecular biology with clinical epidemiology and behavioral science. Key themes include epigenetic regulation of pain and opioid tolerance, neurodegenerative-like changes in cancer, and social determinants of inflammation . Scientific Awards and Recognition: Excellence in Research Mentoring Faculty Teaching Award (2013) Most Dedicated Mentor Award, PMCTR Fellowship Program (2009) Early Career Investigator Award, Bayer Healthcare International (2006) National Liver Scholar Award, American Liver Foundation (2004) Multiple early career and mentoring recognitions (2004–2006) He is an active mentor and collaborator , frequently co-authoring with junior researchers and leading interdisciplinary teams. His work has been supported by NIH-funded initiatives, including the Roadmap K12 program. He is a member of professional societies such as the American Heart Association, American Liver Foundation, and American Society for Human Genetics . He is involved in clinical and translational research teams focused on improving outcomes in cancer, HIV, and chronic pain. His lab and collaborators utilize advanced genomic and bioinformatic tools to uncover mechanisms linking biological systems with patient-reported outcomes. Future work is likely to expand on precision biomarkers, minority stress interventions, and real-time symptom detection using machine learning .

Jukka Alinikulaمشاهده پروفایل

استاد مدعو

• Immunology
• B lymphocytes
• Somatic hypermutation
• +۴ مورد دیگر

Jukka Alinikula is an Adjunct Professor at the University of Turku's Institute of Biomedicine, specifically within the Unit of Infection and Immunity. He also serves as a University Lecturer in immunology and drug development, and as the Education Director of the Immudocs program. His research focuses on somatic hypermutation mechanisms in B lymphocytes, exploring how antibody diversity is generated while avoiding oncogenic mutations. Alinikula completed his PhD at the University of Turku (Lassila Lab), followed by a postdoc at Yale University (Schatz Lab). Research Interests: Alinikula’s work investigates the targeting of somatic hypermutation to immunoglobulin genes versus proto-oncogenes. His lab uses modern techniques like reporter assays, CRISPR-based screens, and single-cell transcriptomics to dissect mutation enhancer functions. Key topics include genome stability, lymphoma etiology, and the interplay between antibody diversification and cancer risk. Teaching: He teaches immunology and immunopharmacology across bachelor’s, master’s, medical, and doctoral programs, emphasizing case-based learning and practical laboratory training. Supervised students include PhD candidates in immunology and drug development. Labs/Teams: Leads his own research group at the Institute of Biomedicine, collaborating extensively with international teams (e.g., Yale, Czech Academy of Sciences). Active in the InFLAMES Flagship initiative for immune system research.

Nathaniel R. Landauمشاهده پروفایل

استاد

• Virology
• Immunology
• Innate Immunity
• +۴ مورد دیگر

Nathaniel R. Landau is a Professor in the Department of Microbiology at NYU Grossman School of Medicine. His research spans HIV molecular biology, dendritic cell immunology, lentiviral vector vaccine development, and SARS-CoV-2 therapeutics. He has pioneered tools for neutralizing antibody assays and developed a soluble ACE2-based therapeutic for coronavirus infections. PhD in Biology from Massachusetts Institute of Technology Postdoctoral Fellowships: University of California, San Francisco (Microbiology & Immunology); MIT Biology Department Dr. Landau's work focuses on innate immunity mechanisms, including restriction factors like APOBEC3 and SAMHD1 that inhibit retroviruses, and how viruses counteract these defenses. His lab has engineered lentiviral vectors that overcome SAMHD1 barriers for dendritic cell transduction and developed second-generation dendritic cell vaccines for HIV and cancer. Recent research includes creating SARS-CoV-2 spike-pseudotyped lentiviruses for neutralization assays and a recombinant ACE2 microbody with enhanced antiviral activity. The lab has validated these tools in convalescent sera studies and developed rapid assays for antibody titers. Key trends in his publications include innate immune evasion, lentiviral vector innovations, and cross-disciplinary approaches to viral pathogenesis. His team has automated neutralization assays using robotic platforms to process large sample volumes efficiently. Dr. Landau's laboratory has contributed to understanding how toll-like receptor agonists like imiquimod induce antiviral states via ISGs, and explored Vpr/Vpx accessory protein functions in lentivirus immune escape. Current projects extend these findings toward immunotherapeutic cancer strategies.

Zackary Fallsمشاهده پروفایل

استادیار

• Biomedical Informatics
• Computational Drug Discovery
• Pharmacoinformatics
• +۹ مورد دیگر

Dr. Zackary Falls is an Assistant Professor in the Department of Biomedical Informatics at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, where he leads a data-centric computational laboratory focused on drug discovery and pharmacoinformatics. Education & Training PhD, Computational Chemistry, University at Buffalo, 2017 BS, Chemistry, Canisius College, 2012 NLM T15 Postdoctoral Fellowship, Jacobs School of Medicine and Biomedical Sciences, 2020 Research Interests His group integrates structural bioinformatics, chemoinformatics, and clinical informatics to develop and apply the multiscale CANDO drug-discovery platform. Current thrusts include: AI-driven design of non-addictive analgesics and overdose-rescue drugs targeting the opioid crisis. Repurposing FDA-approved drugs against COVID-19. Rational design of combination therapies for KRAS-driven non-small-cell lung cancer. Large-scale analytics on EHR and Medicaid claims to understand health disparities in addiction treatment. Scientific Awards Sinsheimer Scholar Award 2024 T15 Informatics Training Fellowship Award 2017 Marjorie Winkler Fellowship Award 2012, Gordon Harris Fellowship Award 2012, Merck Index Award 2012 Funding & Grants Since 2020, Dr. Falls has served as PI or Co-I on grants totaling ≈ $35 million from NIH (NIDA, NCATS, NLM), NIST, Empire AI, and private foundations. Key projects include: Principal Investigator, “A translational bioinformatics approach to elucidate and mitigate polypharmacy-induced adverse drug reactions,” NIDA, $1.05 M, 2022-2027. Co-Principal Investigator, CTSA SUNY Buffalo Hub, NCATS, $29.2 M, 2025-2031. Co-Investigator, “BRIGHT Short-Term Training,” NLM, $0.67 M, 2022-2027. Group & Collaborations He leads the Falls Group , currently mentoring three trainees and collaborating closely with Prof. Ram Samudrala’s team and multiple academic/industry partners. The lab is housed within UB’s Center for Computational Research and the Witebsky Center for Microbial Pathogenesis and Immunology.

John Maciejowskiمشاهده پروفایل

دانشیار

• Cancer Biology
• Genomic Instability
• Innate Immunity
• +۷ مورد دیگر

John Maciejowski, Ph.D., is an Associate Professor in the Molecular Biology Program at the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center. His research bridges cancer biology and innate immunity, focusing on how genomic instability activates immune pathways such as cGAS-STING and drives mutagenesis via APOBEC3 enzymes. His research interests include: Chromosomal instability and micronuclei formation cGAS-STING pathway regulation in cancer APOBEC3-mediated mutagenesis Cancer genome evolution Therapeutic targeting of DNA damage responses The recent publications from the Maciejowski lab highlight a strong focus on the mechanistic regulation of innate immune sensors by cellular nucleases, particularly TREX1, and how these processes influence tumor immunogenicity and genome integrity. The work combines molecular biology, genetics, and cancer models to uncover fundamental mechanisms with translational relevance. His scientific awards include: Pershing Square Sohn Prize Pew Biomedical Scholar V Foundation Scholar Pathway to Independence Award Regeneron Prize for Creative Innovation Tri-Institutional Breakout Prize Jane Coffin Childs Fellowship Dr. Maciejowski mentors trainees and leads an active research program supported by competitive grants. His lab has deposited multiple plasmids at Addgene, indicating collaborative engagement with the broader scientific community. He is involved in key initiatives at the Tri-Institutional level, reflecting deep integration within the New York biomedical research ecosystem. The Maciejowski Lab investigates mechanisms linking genomic instability to innate immune activation, operating at the intersection of cancer biology, DNA repair, and immunology. The lab uses advanced cell models and genetic tools to dissect pathways such as cGAS-STING and APOBEC3, with implications for cancer therapy and genome evolution.

Ashok S. Bhagwatمشاهده پروفایل

استاد

• DNA damage and repair
• Nucleic acid biochemistry
• Carcinogenesis
• +۵ مورد دیگر

Dr. Ashok S. Bhagwat is a Professor in the Department of Chemistry at Wayne State University's College of Liberal Arts and Sciences. He teaches courses including Molecular Biology (CHM6640/CHM7640) and Biological Chemistry Laboratory (CHM6610), with scheduled instruction through Winter Term 2025. His research focuses on DNA damage and repair mechanisms, with particular emphasis on understanding how cellular processes create genomic instability that leads to cancer development. Education: B.Sc., University of Bombay, 1972 M.Sc., Indian Institute of Technology, 1974 Ph.D., Pennsylvania State University, 1982 Postdoctoral Fellow, Cold Spring Harbor Laboratory, 1982-1987 Dr. Bhagwat's research program investigates DNA damage caused by endogenous reactive chemical species, DNA methylation, transcription, replication, and cytosine deamination due to human AID/APOBEC enzymes. His lab studies the interplay between these processes and DNA repair mechanisms in the prevention and promotion of human cancers. They employ a multidisciplinary approach using mass-spectrometry, chemical synthesis, protein and nucleic acid biochemistry, genetics, and cutting-edge cellular and molecular biology methods including genomics and bioinformatics. Analysis of Dr. Bhagwat's recent publications reveals a consistent focus on APOBEC enzymes and their role in DNA damage, particularly in relation to cancer development and potential therapeutic interventions. His work spans virology, cancer biology, DNA repair mechanisms, and the development of novel cancer therapeutics targeting DNA damage pathways. A significant portion of his research examines how uracil formation in DNA contributes to genomic instability and carcinogenesis. Dr. Bhagwat leads the Bhagwat Lab, which has developed innovative tools to quantify and map uracils in genomes. His research has led to the discovery that certain alkoxyamines can specifically kill B cell cancer lines by targeting abasic sites in DNA. His work bridges basic science with potential clinical applications in cancer treatment.

Marc-André Langloisمشاهده پروفایل

استاد

• Molecular Virology
• Intrinsic Immunity
• Retrovirology
• +۷ مورد دیگر

Dr. Marc-André Langlois is a Full Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa's Faculty of Medicine. He serves as Executive Director of the national Coronavirus Variants Rapid Response Network (CoVaRR-Net) and holds the Faculty of Medicine Chair of Excellence in Pandemic Viruses and Preparedness Research. An expert in molecular virology and intrinsic immunity, his work bridges retrovirology (e.g., HIV) and respiratory virus research (e.g., SARS-CoV-2, influenza), with a focus on host-virus interactions. Executive Director, CoVaRR-Net Faculty of Medicine Chair of Excellence, Pandemic Viruses Canada Research Chair in Molecular Virology and Intrinsic Immunity Member, Royal Society of Canada (College) Research interests center on: Host Intrinsic Immunity: Mechanisms of APOBEC3 proteins in restricting retroviruses like HIV Viral Latency: Role of APOBEC3 mutagenesis in HIV persistence Respiratory Virus Serology: High-throughput antibody assays for SARS-CoV-2 and seasonal coronaviruses Mucosal Immunity: Systemic and mucosal responses to vaccines, including intranasal candidates Recent publications highlight expertise in: Immune imprinting in antigenic variation Cross-neutralization of SARS-CoV-2 via seasonal coronavirus antibodies HIV integration site profiling by APOBEC3 enzymes Development of scalable serology platforms Mucosal vaccine characterization Scientific awards include: Canada Research Chair in Molecular Virology and Intrinsic Immunity Faculty of Medicine Chair of Excellence Member, Royal Society of Canada (College) His Serology and Diagnostics High Throughput Facility executed over 2 million assays during the pandemic, supporting 40+ national studies including Statistics Canada's seroprevalence surveys. Research informs federal decision-making through Health Canada and CIHR collaborations.

Matthew D. Weitzmanمشاهده پروفایل

استاد

• Virology
• Virus Replication
• DNA Damage and Repair
• +۶ مورد دیگر

Matthew D. Weitzman is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine and The Children's Hospital of Philadelphia (CHOP). He holds the Arthur Vincent Meigs Endowed Chair in Pediatrics at CHOP and was elected Fellow of the American Academy of Microbiology in 2024. His laboratory is located in the Colket Translational Research Building at CHOP. Dr. Weitzman received his B.Sc. (Honours degree in Genetics) from the University of Leeds, UK (1987) and his Ph.D. in Molecular Virology from Oxford Polytechnic and the Institute of Virology and Environmental Microbiology of the NERC (1991). He completed postdoctoral training as a Fogarty Fellow at NIH (1991-1993) and as a Cystic Fibrosis Foundation Fellow at the University of Pennsylvania Medical Center (1993-1994). His research focuses on the dynamic interactions between viruses and host cells when their genomes are in conflict. He pioneered the study of cellular damage sensing machinery as an intrinsic defense to virus infection, particularly examining how DNA damage responses interact with human DNA viruses. His work revealed that the MRN complex is the mammalian sensor of DNA breaks and viral genomes. His laboratory also studies APOBEC3 proteins and their dual role as antiviral factors and potential contributors to genomic instability and cancer. Analysis of his 15 most recent publications reveals a consistent focus on virus-host interactions, DNA damage responses, and the role of cellular proteins in both defense against viruses and maintenance of genome integrity. His work spans multiple virus families including Adenovirus, Herpes Simplex Virus, and Adeno-Associated Virus, with recent publications exploring biomolecular condensates, viral packaging mechanisms, and the therapeutic implications of APOBEC-mediated mutagenesis in cancer. Natural Environment Research Council (NERC) Graduate Student Scholarship (1984-1987) Young Investigator Award, American Society for Gene Therapy (2004) Foerderer Award, CHOP (2013) CHOP Faculty Mentor Award (2016) Arthur K. Asbury Outstanding Faculty Mentor Award, UPenn (2020) Arthur Vincent Meigs Endowed Chair in Pediatrics (2022-Present) Elected Fellow of the American Academy of Microbiology (2024) Dr. Weitzman has mentored numerous graduate students and postdoctoral fellows, including Amber Abbott and Nick Grams who are listed as graduate students in his laboratory. His lab maintains an interactive and collaborative environment where students and postdocs explore multiple projects including DNA damage responses during virus infection, viral manipulation of host pathways, epigenetic changes during infection, and host restriction factors. His laboratory investigates multiple viruses including Adenovirus (Ad), Herpes Simplex Virus (HSV-1), and Adeno-Associated Virus (AAV), each with different types of DNA genomes that have developed distinct ways of manipulating host defenses. The lab employs an integrated experimental approach combining biochemistry, molecular biology, genetics, and cell biology to probe the dynamic interactions that take place on viral and cellular genomes during infection.

• Molecular Biology
• Biochemistry
• Cancer Genomics
• +۶ مورد دیگر

Reuben Harris is a Professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota Medical School. His research spans multiple disciplines including molecular biology, biochemistry, virology, and cancer genomics, with a particular focus on APOBEC enzymes and their roles in both antiviral defense and cancer development. Dr. Harris's research interests center on the APOBEC family of DNA deaminases, particularly their dual roles in antiviral immunity (especially against HIV) and cancer mutagenesis. His work explores how these enzymes catalyze DNA deamination, the structural and biochemical mechanisms that regulate their activity, and how their mutagenic potential contributes to tumor evolution in various cancers including breast, ovarian, and other malignancies. His research has significant implications for understanding viral restriction mechanisms and developing novel cancer therapeutics targeting APOBEC-mediated mutagenesis. Analysis of his recent publications reveals a consistent focus on APOBEC3 enzymes (particularly APOBEC3A, APOBEC3B, and APOBEC3G), with increasing attention to their structural biochemistry, DNA sequence context preferences, and therapeutic targeting. His work bridges basic enzymology with clinical applications, particularly in cancer genomics and antiviral research, demonstrating how fundamental biochemical insights can inform therapeutic strategies for cancer and viral infections. Dr. Harris has been Principal Investigator on numerous significant research grants, including the Midwest AViDD Center funded by the NIH National Institute of Allergy and Infectious Diseases (2022-2025), projects on APOBEC3B and DNA repair in ovarian cancer funded by the Ovarian Cancer Research Fund (2021-2022), and research on APOBEC mutagenesis in breast cancer funded by Memorial Sloan Kettering Cancer Center and the NIH National Cancer Institute (2020-2022). He also serves as a Co-Investigator on the Department of Defense project targeting N-Myc in neuroblastoma with Aurora kinase A degraders (2021-2025). His laboratory is part of a robust collaborative network focused on DNA repair mechanisms, cancer genomics, and antiviral defense. The research group works closely with structural biologists, computational biologists, and clinical researchers to translate basic findings into potential therapeutic applications. Current projects emphasize understanding how mesoscale DNA features influence APOBEC activity, developing quantitative assays for DNA deamination, and exploring synthetic lethal approaches targeting APOBEC-expressing cancers.

Andrew Macdonaldمشاهده پروفایل

استاد

• Oncogenic viruses
• cell biology
• virology
• +۱ مورد دیگر

Professor Andrew Macdonald is a leading expert in tumour virology at the University of Leeds, holding the position of Professor of Tumour Virology in the School of Molecular and Cellular Biology and serving as Pro-Dean for Research and Innovation in the Faculty of Biological Sciences. His work focuses on understanding how DNA tumour viruses, such as human papillomaviruses (HPV) and polyomaviruses, contribute to cancer and identifying novel therapeutic strategies. He has held roles including Head of the School of Molecular and Cellular Biology (2020–2023) and has been recognized for his research on viral mechanisms and their clinical implications. Education: BSc, University of Leeds PhD in Molecular Biology, University of Leeds (2001) Research Interests: His research integrates virology, oncology, and cell biology to study viral replication, host-pathogen interactions, and antiviral therapies. Key areas include HPV-induced cervical cancer, BK polyomavirus in kidney disease, and the role of cellular signaling pathways in viral persistence. His lab emphasizes interdisciplinary collaboration with clinicians and industry to translate findings into clinical applications. Funding & Grants: Recent funding highlights include a boost for radiotherapy research in Leeds (2024) and studies on BK nephropathy in transplantation (2023). His work has been featured in outlets like the BBC and Yorkshire Post. Labs & Teams: He leads the Macdonald Lab, a well-funded group with state-of-the-art molecular and cellular facilities. The lab fosters a supportive environment for staff and students, emphasizing career development and publication.

Nathan Shererمشاهده پروفایل

استاد

• Molecular Virology
• HIV-1 Biology
• Virus-Host Interactions
• +۱۲ مورد دیگر

Nathan Sherer is a Professor in the Department of Medical Microbiology and Immunology at the University of Wisconsin–Madison, with affiliations in the Bacteriology Department and the UW Carbone Cancer Center. His research integrates live-cell imaging and biochemical approaches to study virus-host interactions, focusing on HIV-1, Hepatitis B virus (HBV), and Human Papillomavirus (HPV). Institution: University of Wisconsin–Madison School: School of Medicine and Public Health Department: Department of Medical Microbiology and Immunology Additional Affiliation: UW Carbone Cancer Center Nathan Sherer earned his BA in Biology from Grinnell College in 1997, followed by a PhD in Microbiology from Yale University in 2006. He completed postdoctoral training at King’s College London before establishing his independent research program at UW-Madison. Dr. Sherer's research centers on the molecular virology of retroviruses, particularly HIV-1. His lab investigates how viral particles assemble and spread through host cells, with a focus on the post-transcriptional journey of HIV-1 genomic RNAs (gRNAs) from the nucleus to the plasma membrane. They utilize cutting-edge live-cell fluorescence microscopy, genetic manipulations, and biochemical assays to dissect virus-host interactions. Key areas include viral RNA transport, ribosomal frameshifting, virological synapse formation, and the role of host proteins in viral replication. The lab has expanded its scope to include HBV and HPV, exploring mechanisms of genome packaging, capsid trafficking, and viral oncogenesis. The recent publications highlight a strong emphasis on imaging technologies, RNA biology, and host factor identification. Articles span super-resolution microscopy development, single-cell analysis of viral gene expression, and proteomic mapping of viral RNA interactomes. Collectively, the work reveals sophisticated strategies viruses use to hijack cellular machinery, offering insights for novel antiviral therapies. Dr. Sherer mentors a dynamic team of graduate students and postdoctoral researchers from programs such as Molecular and Cellular Pharmacology, Cancer Biology, and Cellular and Molecular Biology. His alumni have pursued successful careers in academia, biotechnology, and pharmaceutical research. While no specific scientific awards are listed, his consistent high-impact publications reflect significant contributions to virology. The lab also benefits from collaborative grants and institutional support, enabling advanced imaging and proteomic studies. Dr. Sherer leads an active research laboratory with ongoing projects in HIV-1, HBV, and HPV virology. The team employs a multidisciplinary approach, combining molecular biology, imaging, and biochemistry to understand viral replication mechanisms. Lab members include senior scientists, postdocs, and graduate students working on various aspects of viral assembly, RNA regulation, and host interactions.

Kin Chanمشاهده پروفایل

دانشیار

• Cancer
• Mutagenesis
• Genomics
• +۷ مورد دیگر

Kin Chan is an Associate Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa , conducting research at the intersection of cancer mutagenesis, DNA damage, and genome instability. Education : BSc from Caltech (1998), PhD from University of Washington/Fred Hutchinson Cancer Research Center (2008), Postdoctoral Fellowship at National Institute of Environmental Health Sciences (2016) Research Focus : Molecular origins of cancer mutations, DNA repair mechanisms, and APOBEC3 enzyme-driven hypermutation His work combines wet lab and computational approaches to study mutagenesis signatures in cancers, particularly those induced by environmental agents and enzymatic processes. Recent projects explore repurposing cancer hypermutator enzymes like APOBEC3A for genetic engineering in budding yeast to develop biofuel applications. Key publication trends include mutational signature analysis, DNA damage tolerance, and cross-species genomic instability studies. Dr. Chan's lab webpage provides details for prospective trainees and ongoing research collaborations. Contact: Office in Roger Guindon Hall, Room 4234; Lab in Room 4233; Phone: 613-562-5800 ext. 8574

Linda Chelicoمشاهده پروفایل

استاد

• HIV Restriction Factors
• DNA Deaminases
• Mutagenesis
• +۳ مورد دیگر

Dr. Linda Chelico is a Professor and Department Head of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. Her research focuses on APOBEC cytosine deaminases, studying their roles in HIV restriction and cancer mutagenesis. She leads a lab investigating how these enzymes interact with retroviruses like HIV-1, their mechanisms of DNA deamination, and their unintended oncogenic consequences. Her work bridges virology, biochemistry, and cancer biology, with recent grants exceeding $1.6M from CIHR and NSERC. Education: PhD in Applied Microbiology (USask), postdoctoral training at University of Southern California (USC). Key areas include HIV restriction factors, DNA deaminases, enzyme mechanisms, and mutagenesis. She explores APOBEC interactions with viral proteins (e.g., HIV-1 Vif) and cellular DNA repair pathways, while also examining their role in cancer via mutagenic activity in genomic regions. Research highlights include identifying APOBEC3's dual role as a virus suppressor and cancer mutagen, studying enzyme competition with DNA-binding proteins like RPA, and developing assays to measure deamination activity. Her team's work on HIV-1 transmitted/founder viruses and APOBEC3's structural basis (via SAXS) underscores her interdisciplinary approach. Grants: Over $1.6M from CIHR (2019–2024) for projects on APOBEC3's HIV restriction and cancer links. Collaborations include structural biology (e.g., with Dr. Chen XS on APOBEC3G structure) and proteomic mapping (Krogan lab). Labs focus on biochemical assays, mouse xenograft models, and cross-disciplinary techniques. Publications (2024–2021) emphasize APOBEC3F/G interactions, enzyme purification, and their roles in SIV transmission and bladder cancer mutagenesis. Her work is published in Journal of Virology , Molecular and Cellular Proteomics , and Nature Communications .

Pedram Razaviمشاهده پروفایل

استادیار بالینی

• Breast Cancer Genomics
• Precision Oncology
• Liquid Biopsy
• +۳ مورد دیگر

Pedram Razavi serves as a Clinical Assistant Professor within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC), where he holds appointments in the Breast Medicine Service and Solid Tumor Oncology Division. His clinical and research activities focus exclusively on advancing precision oncology for breast cancer patients through genomic and computational approaches. Dr. Razavi's research program centers on decoding the genomic architecture of metastatic breast cancer to develop predictive biomarkers and optimize therapeutic strategies. His work spans three critical domains: (1) liquid biopsy development for real-time ctDNA monitoring during CDK4/6 inhibitor therapy, (2) machine learning integration of multimodal data to predict real-world progression-free survival, and (3) mechanistic studies of mutational drivers like APOBEC3 and ERBB2 in therapy resistance. Recent investigations reveal how double PIK3CA mutations in cis configuration enhance oncogenicity while increasing PI3Kα inhibitor sensitivity, and how ERBB2 activating mutations enable trastuzumab deruxtecan efficacy in HER2-non-amplified disease. Analyzing his 184 publications (including 18 in 2025), a clear trajectory emerges toward clinically actionable genomic insights. Over 70% of his recent work appears in high-impact journals like Journal of Clinical Oncology (42 publications) and Cancer Research (26), with meeting abstracts dominating his 2025 output reflecting active clinical trial engagement. His research consistently bridges basic mechanisms (e.g., APOBEC3 mutagenesis driving resistance) with immediate clinical applications (e.g., ctDNA dynamics predicting treatment response). Dr. Razavi maintains an extensive collaborative network centered at MSKCC, with Sarat Chandarlapaty (79 co-publications), Jorge Reis-Filho (67), and Michael Berger (45) representing his core team. He actively participates in international initiatives like the Buenos Aires Breast Cancer Symposium, demonstrating global leadership in translating genomic discoveries into clinical practice for metastatic breast cancer.